Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (81-90 of 334) with videos related to

Pageof 34
Sort By:
Rheumatology and Therapy|January 12, 2026
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA)Georg Pongratz, Rieke Alten, Torsten Witte, et al.
Annals of the Rheumatic Diseases|May 22, 2007
N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis?Thomas Häupl, Gerd R Burmester, Evangelos Giannitsis, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA studyPaul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Arthritis and Rheumatism|June 28, 2006
Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28Michael Brychcy, Ulrike Kuckelkorn, Gert Hausdorf, et al.
Arthritis and Rheumatism|June 28, 2006
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and TedderDavid M Goldenberg, Rhona Stein, John P Leonard, et al.
Annals of the Rheumatic Diseases|November 12, 2024
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaborationKenneth Frank Baker, Julia Spierings, Martin Brom, et al.
Annals of the Rheumatic Diseases|August 31, 2011
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteriaChristof Iking-Konert, Martin Aringer, Jürgen Wollenhaupt, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaborationKenneth Frank Baker, Julia Spierings, Martin Brom, et al.
The Journal of Rheumatology|March 17, 2019
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study SubanalysisJürgen Braun, Xenofon Baraliakos, Uta Kiltz, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)Christopher Schneeweis, Michael Rafalowicz, Eugen Feist, et al.
Pageof 34

Showing results (81-90 of 334) with videos related to

Sort By:
Pageof 34
Rheumatology and Therapy|January 12, 2026
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA)Georg Pongratz, Rieke Alten, Torsten Witte, et al.
Annals of the Rheumatic Diseases|May 22, 2007
N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis?Thomas Häupl, Gerd R Burmester, Evangelos Giannitsis, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA studyPaul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Arthritis and Rheumatism|June 28, 2006
Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28Michael Brychcy, Ulrike Kuckelkorn, Gert Hausdorf, et al.
Arthritis and Rheumatism|June 28, 2006
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and TedderDavid M Goldenberg, Rhona Stein, John P Leonard, et al.
Annals of the Rheumatic Diseases|November 12, 2024
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaborationKenneth Frank Baker, Julia Spierings, Martin Brom, et al.
Annals of the Rheumatic Diseases|August 31, 2011
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteriaChristof Iking-Konert, Martin Aringer, Jürgen Wollenhaupt, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaborationKenneth Frank Baker, Julia Spierings, Martin Brom, et al.
The Journal of Rheumatology|March 17, 2019
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study SubanalysisJürgen Braun, Xenofon Baraliakos, Uta Kiltz, et al.
Clinical and Experimental Rheumatology|April 24, 2010
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)Christopher Schneeweis, Michael Rafalowicz, Eugen Feist, et al.
Pageof 34